448 Background: As an increasing number of biomarker-driven therapies get approved, the burden on the oncology provider to keep track of approved therapies has increased. Further, most of the genomic findings are trapped in unstructured documents and are not easily searchable within the electronic medical record (EMR). We circumvented these issues in a pilot study by creating physician alerts that highlight actionable biomarker-driven therapies and institutional trials, making them easily accessible to oncology providers. Methods: Provider Messaging for Precision Treatments (ProMPT) service is being piloted at a large community oncology practice site with 29 oncology providers. Leveraging the raw genomic data feed from NGS vendors, we perform a weekly query for all the patients with a molecular test signed in the past week. We then examine the diagnoses and the identified mutations for the patients to match FDA approved precision therapies and institutional trials (genomic and diagnosis-based). The findings are recorded in a tabular format and sent weekly to providers via email to assist them in choosing the best therapy for their patients. Results: In the 12 weeks since launch, we have reviewed 1274 mutations from 114 unique patients. In addition, we also highlighted findings that warranted germline counseling/testing (based on the variant allele frequency), additional testing (lack of a clear driver mutation), and biomarkers that may confer resistance to treatment via targeted therapy or immunotherapy. Conclusions: Creating automated services that alleviate provider burden to recall and recommend appropriate therapies by surfacing actionable genomic findings when the NGS results first become available can ensure that all patients receive the best care. Services such as ProMPT are needed to effectively deliver on the promise of personalized medicine.[Table: see text]